Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Free Cash Flow (2024 - 2025)

Historic Free Cash Flow for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$17.5 million.

  • Xilio Therapeutics' Free Cash Flow fell 2787.81% to -$17.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.6 million, marking a year-over-year change of. This contributed to the annual value of -$18.4 million for FY2024, which is 7335.4% up from last year.
  • As of Q3 2025, Xilio Therapeutics' Free Cash Flow stood at -$17.5 million, which was down 2787.81% from -$14.6 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Free Cash Flow ranged from a high of $28.7 million in Q1 2025 and a low of -$17.5 million during Q3 2025